|
Clinical Utility of Glimepiride and Metformin Fixed-Dose Combination in Obese/Overweight Patients with Type 2 Diabetes Mellitus in Indian Settings
Binayak Sinha1, Saket Kant2, Sabyasachi Bandyopadhyay3, Sagarika Mukherjee4, Dasarathi Sarkar5, Kiran P Singh6, Tirthankar Chaudhury3, Surender Kumar7, Rahimuddin Ahmed8, Mahesh Abhyankar9, Ashish Prasad9, Mayuri Talathi9
1 Department of Endocrinology, AMRI Hospital-Salt Lake; Department of Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal, India
2 Ananda Medicare, Gurudwara Sant Samagam, Rohini, Delhi, India
3 Department of Endocrinology, Apollo Gleneagles Hospital, Kolkata, West Bengal, India
4 Dr. Sagarika Mukherjee's Clinic, Kolkata, West Bengal, India
5 Department of Endocrinology, S.S.K.M Hospital, Kolkata, West Bengal, India
6 Department of Endocrinology, Fortis Hospital, Mohali, Punjab, India
7 Department of Endocrinology, Shri Ganga Ram Hospital, Delhi, India
8 Ahmed Diabetes Care Centre and Life Style Clinic, Kacharigoan, Assam, India
9 Scientific Services, USV Private Limited, Mumbai, Maharashtra, India
Correspondence Address:
Mayuri Talathi
Scientific Services, USV Private Limited, Mumbai, Maharashtra
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/cdrp.cdrp_5_22
|
|
Background: In India, glimepiride has become a promising option for add-on therapy with metformin in patients with type-2 diabetes mellitus (T2DM) owing to its efficacy, safety, and cost-effectiveness. This study aimed to analyze the clinical utility of multiple strengths of glimepiride and metformin fixed-dose combination (FDC) in obese/overweight patients with T2DM. Methods: This case-based questionnaire survey was conducted between June 2020 and June 2021 and included health-care professionals across India to assess the usage pattern of glimepiride and metformin FDC. Results: Overall, data from 1345 patients taking multiple strengths of glimepiride and metformin FDC were analyzed, of which 64.7% were men. A total of 57.6% of patients were overweight, 29.4% were obese Class I, 9.6% were obese Class II, and 3.4% belonged to obese Class III. Sedentary lifestyle (60.3%), smoking (36.7%), and emotional stress (33.3%) were the most common risk factors. Among the available strengths, glimepiride 2 mg and metformin 500/850/1000 mg FDC was most widely used in 50.5% and 47.4% of patients from overweight and obese groups, respectively. A total of 90.3% and 89.1% of patients, respectively, from the overweight and obese groups did not observe weight gain. The majority of the patients from overweight and obese groups observed blood pressure within optimum levels (68.5% and 71.4%, respectively). The mean glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels were significantly reduced with posttreatment of glimepiride and metformin FDC with a mean change of 1.4%, 44.3 mg/dL, and 73.5 mg/dL, respectively (P < 0.01). The physician global evaluation of efficacy (90.3%) and tolerability (91.1%) showed the majority of the patients on a good to excellent scale. Conclusion: The real-world evidence in the Indian clinical setting indicates that the glimepiride and metformin FDC was found to be effective in achieving glycemic control and it is observed to be safer in terms of weight gain and hypoglycemia.
|
